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The tryptophan (TRP) to kynurenine (KYN) metabolic pathway is now firmly established
as a key regulator of innate and adaptive immunity. A plethora of preclinical models sug-
gests that this immune tolerance pathway – driven by the key and rate-limiting enzymes
indoleamine-2,3-dioxygenase and TRP-2,3-dioxygenase – is active in cancer immunity,
autoimmunity, infection, transplant rejection, and allergy. Drugs targeting this pathway,
specifically indoleamine-2,3-dioxygenase, are already in clinical trials with the aim at revert-
ing cancer-induced immunosuppression. In the past years, there has been an increase in
our understanding of the regulation and downstream mediators ofTRP metabolism, such as
the aryl hydrocarbon receptor as a receptor for KYN and kynurenic acid.This more detailed
understanding will expand our opportunities to interfere with the pathway therapeutically
on multiple levels. Here, we discuss the perspective of targetingTRP metabolism at these
different levels based on reviewing recent insight into the regulation of TRP metabolism
and its downstream effectors.
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INTRODUCTION
The catabolism of the essential amino acid tryptophan (TRP) is
a central pathway maintaining the immunosuppressive microen-
vironment in many types of cancers. The classic concept proposes
that tumor cells or myeloid cells in the tumor microenvironment
or draining lymph nodes express high levels of indoleamine-2,3-
dioxygenase 1 (IDO1), which is the first and rate-limiting enzyme
in the degradation of TRP. This enzymatic activity results in the
depletion of TRP in the local microenvironment and subsequent
inhibition of T cell responses. T cells sense low TRP levels via
uncharged tRNAs and subsequently activating the kinase general
control non-derepressible 2 (GCN2) and initiating an amino acid
starvation response resulting in cell cycle arrest and cell death. This
rather non-specific metabolic pathway exerts immunosuppression
in the local microenvironment as T cells are particularly sensi-
tive to low TRP levels. This IDO1-centered concept is supported
by numerous preclinical studies in models of tumor immunity,
autoimmunity, infection, and allergy. More recent preclinical stud-
ies, however, propose an alternative route of TRP degradation in
tumors via the enzyme TRP-2,3-dioxygenase 2 (TDO), which was
previously believed to be liver- and neuron-specific. Tumor cells
and possibly specialized myeloid cells may express and catabolize
TRP via TDO instead of or in addition to IDO1. Thus, TDO may
represent an additional target for cancer immunotherapy, while
both enzymes ought to employ identical downstream effectors,
such as GCN2.
The effector function of GCN2 in the context of cancer immu-
nity, however, is less well understood and established. In addi-
tion, several studies have proposed that immunosuppression by
TRP degradation is not solely a consequence of lowering local
TRP levels but also of accumulating high levels of TRP metabo-
lites. This alternative or additional concept is supported by stud-
ies demonstrating that T cell responses are inhibited by TRP
metabolites, mainly by binding to the aryl hydrocarbon recep-
tor (AHR), a cytoplasmic transcription factor, previously believed
to be solely responsible for detoxification of polyaromatic hydro-
carbons. The importance of the AHR in regulating autoimmunity
and tumor immunity is supported by preclinical studies and analy-
ses of human tumor tissue demonstrating that binding of the
TRP metabolite kynurenine (KYN) to the AHR results in repro-
graming the differentiation of naïve CD4+ T-helper (Th) cells
favoring a regulatory T cells phenotype (Treg) while suppress-
ing the differentiation into interleukin-17 (IL-17)-producing Th
(Th17) cells. Notably, activation of the AHR also results in pro-
moting a tolerogenic phenotype on dendritic cells (DC). The
AHR seems to be required for the induction of IDO in dendritic
cells (1) and stimulation with the poisonous AHR-agonist 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) was shown to induce IDO
expression in dendritic cells (DC) (2), suggesting a feed-forward
loop of immunosuppressive TRP metabolism. The role of the AHR
on CD8+ effector T cells is less well understood.
While first clinical trials with IDO1 inhibitors are underway,
this review aims at putting the recent advances in understand-
ing the immunobiology of TRP catabolism via IDO1/TDO in
therapeutic perspective for cancer immunotherapy.
MULTIPLE THERAPEUTIC TARGETS IN TRYPTOPHAN
CATABOLISM
Current preclinical studies suggest that the opportunity to inter-
fere with immunosuppressive TRP catabolism goes well beyond

























































Platten et al. Cancer immunotherapy by targeting IDO1/TDO
restoring TRP levels by inhibiting the enzymatic activity of IDO1.
First, tumors may catabolize TRP by alternative enzymatic routes
such as TDO. A survey of cancer cell lines indicates that 16% of
tumor cell lines are IDO1 positive, while 19% are TDO positive
and 15% express both TDO and IDO1 (3). These observations
suggest that targeting TDO may complement IDO1 inhibition.
Remarkably, IDO1 inhibitors available to date do not cross-inhibit
TDO and vice-versa, probably due to low sequence homology of
these two enzymes despite similar enzymatic properties. Second,
several studies have indicated that IDO1 is intricately linked to
an oncogenic signaling pathway, opening new therapeutic avenues
to inhibit IDO on a more upstream transcriptional or transla-
tional level. Promising upstream targets of IDO1 include KIT,
signal transducer and activator of transcription 3 (STAT3), and the
tumor suppressor Bin1 (4–6). Also, there is new evidence of IDO1
promoting self-tolerance via non-enzymatic signaling pathways
involving transforming growth factor-β (TGF-β) (7). This non-
enzymatic activity of IDO1 would only be targeted by strategies
interfering with upstream pathways regulating IDO1 transcrip-
tion and/or translation. Third, low TRP levels, which are believed
to mediate to a relevant extent the immunosuppressive activity
of IDO1, are sensed by the stress kinase GCN2 activated in T
cells in low TRP conditions. The specific pathways transducing the
immunosuppressive signals by activated GCN2 in T cells are yet to
be identified. Alternatively or in addition, low TRP levels may be
sensed by the signaling complex mammalian target of rapamycin
(mTOR), which may provide a TRP sufficiency signal not only
in cancer cells but also in T cells. Fourth, TRP metabolites such
as KYN, 3-hydroxy-kynurenine (3-HK), and kynurenic acid (KA),
which may accumulate in the local microenvironment due to high
activity of IDO1 and/or TDO, actively suppress T cell responses.
These activities are – at least in part – mediated by binding to the
AHR, which is – among other effects – involved in the control of
differentiation and activation of Tregs. The role of the orphan G
protein-coupled receptor GPR35 as a receptor for KYN and KA in
immunity is currently unclear. Fifth, transcellular transport sys-
tems responsible for shuttling TRP and its metabolites in and out
of its target cell include several promiscuous but possibly other
more specific transporters whose function in regulating immune
responses are not well understood, but, which may serve as poten-
tial therapeutic targets, for instance, with the aim at maintaining
high intracellular TRP levels in immune effector cells despite low
extracellular TRP levels.
Conceptually, these five distinct hubs may serve as poten-
tial therapeutic targets interfering with immunosuppressive TRP
catabolism in the context of cancer and possibly other immune-
mediated diseases associated with an activation of TRP metab-
olism (Figure 1). The potential therapeutic opportunities and
challenges associated with these hubs are discussed in the following
chapters.
TARGETING IDO1: FINDING THE RIGHT COMBINATION
PARTNER
IDO1 is now firmly established target of drug discovery in can-
cer immunotherapy. The first IDO1-inhibitor, 1-methyl-TRP, is
a mixture of the two racemic isoforms 1-methyl-l-TRP (1-l-
MT) and 1-methyl-d-TRP (1-d-MT). While 1-l-MT is the classic
non-competitive inhibitor of IDO1, 1-d-MT has been suggested
to be less active in inhibiting IDO1 (8), but showing higher
potency in reversing IDO-mediated T cell suppression (9, 10).
1-d-MT is being developed clinically as an IDO-inhibitor (indox-
imod, NLG8189) for the treatment of several cancers with the aim
at reversing cancer-associated immune suppression. Reversal of
tumor-associated immune suppression by 1-d-MT appears to be
dependent on host IDO1 expression in preclinical models (9). In
addition or alternatively to direct IDO inhibition, 1-d-MT may
interfere with transcellular TRP transport (11), thereby provid-
ing via mTOR a TRP sufficiency signal to the cell (12) and by
additional off-target effects (13). As 1-l-MT is principally capa-
ble of exerting the same effects, it is not yet entirely clear why
1-d-MT is more effective in restoring T cell activity under phys-
iological conditions (12). 1-d-MT was reported to preferentially
target IDO2 (8). IDO2 is an IDO-related enzyme with a different
expression pattern. The physiological relevance of IDO2 partic-
ularly in humans remains unclear (8, 10, 14); further studies are
required to determine whether it may serve as a suitable target for
cancer immunotherapy.
In addition to directly inhibiting IDO enzymatic activity,
second-generation IDO1 inhibitors such as INCB024360 may
have a more favorable pharmacokinetic profile. While phase I
clinical trials with these orally available compounds have demon-
strated safety (15) and indicated biological efficacy based on serum
parameters demonstrating reversal of TRP depletion and KYN
accumulation, it is questionable whether these compounds will be
effective by themselves. The major challenge for designing future
clinical trials will be to find the appropriate combination part-
ner. In this respect, preclinical studies have provided valuable
insight into potential strategies to amplify the efficacy of IDO1
inhibitors. Initial experiments have applied 1-MT in combina-
tion with chemotherapy (6). Consequently, clinical phase I trials
have combined indoximod with chemotherapy (16–18). Based on
early observations that IDO1 is induced in DCs following ligation
of B7 molecules by cytotoxic T-lymphocyte-associated protein 4
(CTLA4) (19–21), a recent preclinical study suggested that IDO1
is a critical resistance mechanism attenuating the efficacy of anti-
CTLA4 antibodies in cancer immunotherapy. Interestingly, in this
study this crucial role as a resistance factor is not restricted to anti-
CTLA4 antibodies but also antibodies to programed cell death 1
(PD-1) and programed death-ligand 1 (PD-L1) (22). Trials com-
bining indoximod (23) or INCB024360 (24) with the anti-CTLA4
antibody ipilimumab in patients with melanoma are underway.
Conceptually and also supported by preclinical studies, IDO1 inhi-
bition may enhance the efficacy of active cancer vaccines as it may
break cancer-induced tolerance. Two phase II studies are currently
evaluating this combination approach (25, 26).
It has been shown that prostaglandin E2 (PGE2) expression
in a cancer setting induces regulatory T cells, promotes T cell
anergy through direct effects on T cells and indirect effects via
antigen presenting cells (APCs) (27), thus, like IDO, shifting the
immune system toward a tolerogenic phenotype and promoting
tumor progression. Cyclooxygenase 2 (COX2), key enzyme in the
production cascade of PGE2, like IDO, is expressed at low levels
by most somatic cells but is upregulated in many types of can-
cer cells and tumor-infiltrating APC (27). Interestingly, PGE2 may
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FIGURE 1 | Schematic representation ofTRP catabolism in the tumor
microenvironment: expression of indoleamine-2,3-dioxygenase (IDO) and
tryptophan-2,3-dioxygenase (TDO) by tumor cells and infiltrating immune
cells leads to depletion of the essential amino acid tryptophan (TRP) while
metabolites such as kynurenine (KYN) accumulate. Upon binding of TRP
catabolites, the aryl hydrocarbon receptor (AHR) translocates to the nucleus,
dimerizes with AHR nuclear translocator (ARNT), and induces the expression
of its target genes by binding to dioxin-responsive elements (DRE). In tumor
cells, expression of IDO seems to be linked to oncogenic signaling pathways
such as loss of tumor suppressor gene Bin1 with subsequent STAT1 and
NFκB activation, and STAT3 activation through mutated receptor tyrosine
kinases such as KIT. IDO expression in APCs seems to be associated with a
regulatory phenotype and is among others driven by AHR activation, cell–cell
contact with tumor cells, and Tregs through PD-1/PD-L1 or B7/CTLA4
interaction (not shown), and soluble factors such as PGE2, IFNγ, VEGF, and
IL-10. In most cell types, transcellular TRP transport is handled by light chain
glycoprotein-associated amino acid transporters (LAT) functioning as
TRP/KYN antiporters. IDO expressing tumor cells and APCs additionally
express high-affinity TRP transporters leading to a shift of remaining TRP
away from highly TRP-dependent T cells. There, general control
non-derepressible 2 (GCN2) activation through accumulation of unloaded
tRNAs, mTOR signaling, and AHR activation lead to inhibition of CD8+
effector T cells while differentiation of Tregs is enhanced. These Tregs
together with tolerogenic APCs further inhibit an effective anti-tumor
immune response by release of immunosuppressive cytokines and inhibitory
cell surface proteins.
be part of the immunosuppressive KYN-AHR feed-forward loop
by driving IDO and TDO [Ref. (28) and unpublished observa-
tions]. It seems reasonable that suppression of anti-tumor immu-
nity via PGE2 and IDO are not separately working mechanisms
but rather contribute synergistically to tumor immune evasion.
Thus, a combinatorial approach with IDO- and COX2-inhibitors
might be an interesting option to break suppression of anti-cancer
immunity.
Besides finding the right combination partner, a future chal-
lenge will certainly be the identification of cancer types and
patients who will benefit from an IDO1 inhibitory approach.
Current trials do not select patients based on IDO1 expres-
sion in tumor tissue or assessment of systemic IDO1 activity
by analysis of TRP and its metabolites in patients’ serum. It is
conceivable that this approach may be most successful in can-
cer types, which are immunogenic per se, such as malignant
melanoma. Another challenge will certainly be the assessment of
possible escape strategies that cancers may develop. There is essen-
tially no data on such potential evasion strategies in preclinical
studies.
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NON-ENZYMATIC TARGETING OF IDO1
In the past years, it has become increasingly clear that IDO1 is
part of an oncogenic signature in cancer supporting the concept
that cell-autonomous pathways driving cancer cells are intricately
linked to an immunosuppressive phenotype (29). For instance,
IDO1 is controlled by the tumor suppressor gene Bin1 encoding
the Myc-box-encoding protein 1. Loss of Bin1 in tumors results
in transcriptional upregulation of IDO1 via STAT1 and nuclear
factor (NF)-kB and subsequent escape from T cell-dependent anti-
tumor immunity (6). In addition, a recent study suggests that
IDO1 is also driven by oncogenic KIT signaling in gastrointestinal
stromal tumors (GIST). Treatment of experimental tumors with
imatinib resulted in the reversal of IDO1-mediated immunosup-
pression and thus activation of T effector cells and suppression
of Tregs, which was dependent on IDO1, which was suppressed
by imatinib (4). These data suggest that this targeted agent may
derive its remarkable clinical effects in this tumor entity from
its profound immunological effects and advocate for conducting
preclinical studies in tumor models involving immunocompetent
hosts. Based on the link between CTLA4 and IDO1, a ratio-
nal therapeutic consequence of this observation is to combine
imatinib with an anti-CTLA4 approach in GIST, which is cur-
rently tested in a clinical trial (30). IDO1 expression, which is
classically induced by proinflammatory cytokines, is tightly con-
trolled by STAT molecules. These pathways are also activated by
oncogenic signaling pathways. For instance, STAT3, which is acti-
vated by KIT and also growth factors such as epidermal growth
factor (EGF) and cytokines such as IL-6 transcriptionally acti-
vates IDO1 by binding to its promoter (5). As new compounds
targeting, for instance, activated STAT3 are now in clinical tri-
als (31), there is a great opportunity for investigating, whether
the beneficial and potentially immunostimulatory effects of these
agents are also dependent on IDO1. The same mechanisms that
mediate transcriptional or translational activation of IDO1 may
affect its stability. For instance, the STAT antagonist suppressor
of cytokine signaling (SOCS) 3 promotes the active protein to
bind IDO1 and promote its proteasomal degradation (32). This
intriguing observation further strengthens the rational to interfere
with IDO protein expression in addition or alternatively to IDO1
enzyme inhibition. Along this line are preclinical and clinical stud-
ies targeting IDO1 by a peptide vaccine (33). Here, it will be
fascinating to see how elimination of IDO-expressing cells will
alter the immunosuppressive tumor microenvironment and allow
for a more efficient anti-tumor immunity. We are only beginning
to understand the complex network interacting with IDO1. This
complexity is even increased by recent observations that IDO1
may act as a signaling molecule mediating or sustaining immune
tolerance independent of its enzymatic activity (7). This observa-
tion further supports the concept that IDO1 in cancer immune
therapy ought to be targeted not only at the enzymatic level.
TARGETING TDO: AIMING AT A LIVER ENZYME
With two recent studies demonstrating that TRP metabolism via
TDO represents an alternative route to IDO1 activity employed by
tumors (3, 34), there is an interest in pharmacological targeting
of TDO for cancer immunotherapy. This interest is fueled by the
fact that currently available IDO1 inhibitors do not target TDO.
Based on the lead structure of 68OC91 (35), the indole LM10 has
recently been developed with a more favorable pharmacokinetic
profile (36). One concern of systemic TDO inhibition is safety. In
contrast to IDO1, TDO is strongly expressed constitutively in the
liver, where it is believed to be responsible for maintaining sys-
temic TRP levels, and – albeit at lower levels – in neurons. There
are two lines of evidence that TDO may be targeted safely with
a specific inhibitor: currently, preclinical studies have not docu-
mented relevant liver toxicity using LM10 (3) and TDO-deficient
mice develop normally and display an unremarkable phenotype
except for an increased neurogenesis and a less anxious phenotype
(37). The latter may be due to increased levels of 5-hydroxy-TRP
(5-HTP) in the hippocampus. While these may be beneficial effects
in some diseases, CNS-specific side effects ought to be closely
monitored in future preclinical and clinical studies. It also needs
to be taken into consideration that systemic TDO inhibition will
result in increased levels of TRP metabolites such as KYN due to
increased availability of TRP for IDO1 as suggested by the TDO-
deficient mice. If TRP metabolites are relevant in mediating the
immunosuppressive and tolerogenic effects of TRP catabolism in
cancer, a dual approach needs to be considered to combine an anti-
TDO strategy with inhibitors of KYN. In addition to identifying
novel TDO inhibiting compounds, it is logical to test – based on
the experiences with IDO1 – existing anti-cancer compounds for
their potential to inhibit TDO (38). Here, the understanding of the
signaling pathways driving constitutive TDO expression in tumor
cells is key to interfere with this pathway. First studies aiming at
deciphering these pathways have just been published and reveal
fundamental differences in the regulation of TDO in cancer cells
versus untransformed cells (39).
TARGETING AHR: CHALLENGING A PROMISCUOUS
RECEPTOR
Several metabolites of TRP including photoproducts such as 6-
formylindolo-[3,2-b]carbazole (FICZ) (40), bacterial products
such as indole-3-aldehyde, phenazines, and naphthoquinones (41,
42), and plant products such as indoles, flavonoids, and polyphe-
noles (43) have been shown to be ligands of the AHR. Since the
discovery that AHR-deficient mice are prone to autoimmunity
(44, 45) and that mice expressing a constitutively active AHR
are prone to develop tumors (46), it has been speculated that
endogenous TRP metabolites are responsible for inducing AHR-
mediated tolerance. Indeed, a recent study has demonstrated that
TRP metabolites produced by IDO1 and/or TDO induce tolerance
to bacterial products via the AHR (47). This study is important
as it supports the concept that endogenous TRP levels produced
by IDO1/TDO accumulate at levels sufficient to activate the AHR.
Of note, the IC50 of KYN and KA for the AHR is in the low
micromolar range (34, 48). As tumors produce high levels of
these metabolites in the order of 30–50µM, it comes as no sur-
prise that the levels are sufficient to activate the AHR (34). As
preclinical studies also suggest that the AHR is responsible for
mediating – at least in part – the immunosuppressive effects of
cancer-derived TRP metabolites (34, 48), the AHR represents a
logical pharmaceutical target for cancer immunotherapy. Several
challenges have to be met in developing AHR antagonists to cancer
immunotherapy: first, the AHR is a promiscuous receptor binding
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several structurally diverse molecules with different affinity. Many
studies evaluating AHR ligands rely on luciferase assays measuring
the transcriptional activity of dioxin responsive elements (DRE)
bound by the AHR. Often times, however, compounds, which
induce AHR-dependent DRE activity, are not direct AHR ligands
but rather facilitate its activity as a transcription factor. Here, the
fact that it has not been possible to date to crystallize the AHR for
receptor–ligand interaction studies has been an important hurdle
in the development of drugs binding to the AHR. Clearly, due to
its promiscuity, screens based on cellular luciferase assays have to
cope with a high hit rate. On the other hand, there are compounds
already available with AHR antagonistic activity. Whether these
compounds are capable of blocking all AHR ligands including
TRP metabolites is unclear. Second, there are safety concerns with
respect to pharmacological AHR inhibition. While AHR knock-
out mice develop normally and display only mild immunological
aberrations including deficiency of specific resident immune cells
in the gut and skin, challenge of these mice with drugs, which are
metabolized via the AHR, may result in toxicity, which would also
be observed in patients treated with AHR antagonists. Third, it is
not entirely clear, which cellular and molecular mechanisms are
involved in AHR-mediated tolerance to tumors. As AHR activa-
tion has been shown to induce a tolerogenic phenotype in DCs
and modulate Treg differentiation, it may well be possible that the
AHR acts at multiple levels of the immune compartment. Clearly,
further studies are warranted to clarify these challenges before
moving AHR antagonistic strategies to the clinic.
TARGETING GCN2: INTERFERING WITH MULTIPLE
PATHWAYS
The classical effector pathway of immunosuppressive TRP metab-
olism involves the activation of the stress kinase GCN2. GCN2
is activated by uncharged tryptophanyl tRNAs accumulating in
conditions of low TRP levels. Interestingly, although GCN2 has
been suggested as a key mediator of the T cell suppressive effects
of low TRP conditions (49), remarkably little is known about how
GCN2 regulates T cell function. While in low TRP environments,
GCN2 in CD8+ effector T cells is important for induction of
anergy following TCR stimulation (49), in CD4+ T cells GCN2
appears to be important for the expansion and activation of regu-
latory T cells (50). Of note, GCN2 is also expressed in DCs where
it appears to aid antigen presentation by regulating autophagy.
While it is in principle conceivable that GCN2 may be a thera-
peutic target in the immunosuppressive TRP pathway, there are
several challenges ahead: first, GCN2 is ubiquitously expressed
and important in regulating response not only to amino acid
deprivation but also to other forms of cellular stress including
UV irradiation. Again, GCN2-deficient mice are remarkably nor-
mal but display abnormalities in regulating body weight owing
to a crucial role of neuronal GCN2 in regulating eating behav-
ior in response to nutritional cues. As cellular stress is a crucial
hallmark of cancer affecting tumor cells and the tumor stroma,
further studies are required to delineate the role of GCN2 in this
context. Also remarkably, there is no evidence that host GCN2 is
relevant in regulating tumor immunity in transplantable or spon-
taneous syngeneic tumor models not requiring adoptive transfer of
antigen-specific T cells. Clearly, these studies have to be performed,
also to enable the identification of key signaling pathways involved
in GCN2-mediated alteration of T cell function in response to
tumors with active TRP metabolism.
TRP TRANSPORT PATHWAYS – AN UNDERRECOGNIZED
VARIABLE
Induction of TRP dioxygenase enzyme activity in general may
result in a dramatic drop in extracellular TRP levels. The obser-
vation, for instance, that IDO-mediated immune suppression can
be reversed in certain paradigms by supplementing TRP has led to
the hypothesis that the depletion of extracellular TRP suppresses
T cell function (51). This hypothesis, however, is based on the pre-
sumption that extra- and intracellular TRP pools are equilibrated.
Transmembrane TRP transport is chiefly regulated by two dis-
tinct systems: the T-system (T-type amino acid transporter, TAT)
and the l-system (light chain glycoprotein-associated amino acid
transporter, LAT). Most cell types use the l-system to transport
TRP across the cell membrane. The placenta, for instance, which
is an organ with high IDO activity, solely relies on the l-system to
achieve TRP influx (52). The l-system is a heterodimeric trans-
membrane receptor consisting of a heavy chain (4F2hc, CD98hc)
and a light chain (LAT1 or LAT2), the latter representing the cat-
alytic subunits. Interestingly, the l-system is identical with CD98,
a cell surface receptor originally identified as an antigen expressed
on the cell surface of tumor cells and activated T cells (53). CD98hc
interacts with and modulates the cell adhesion properties of inte-
grins (54). System L is commonly overexpressed in tumor cells
and seems to be the main route for transcellular TRP transport
in T cells (55). Myeloid APCs have been shown to express an
additional high-affinity TRP transport mechanism (55) thus being
able to take up TRP efficiently in a low TRP containing microen-
vironment. We have previously shown that System L functions
as a TRP/KYN antiport system using a FRET-based TRP sen-
sor (56). While T cells respond to low extracellular TRP levels
with growth arrest and anergy, IDO-expressing tumor cells and
myeloid APCs might maintain sufficient intracellular TRP lev-
els through KYN/TRP exchange and high-affinity TRP transport.
Hence, under TRP depleting conditions, such as cancer, it seems
likely that T cells are more affected by TRP starvation and TRP
is efficiently being shifted toward TRP consuming cells. The l-
system not only binds TRP but also structurally related molecules.
The commonly used IDO-inhibitor 1-methyltrypophan (1-MT),
for instance, binds LAT1 in breast cancer cells and suppresses TRP
influx and enhances TRP efflux (11).
By employing the same transcellular transport mechanisms,
1-d-MT may act as a TRP mimetic, as outlined above, and pro-
vide an intracellular TRP sufficiency signal maintaining mTOR
activity also in T cells, thus restoring their activity (12). Whether
cancer cells rely on TRP metabolism to maintain their NAD levels
or whether this pathway represents a rescue system when de novo
NAD synthesis is not sufficient to provide energy under certain
circumstances has not been analyzed.
Collectively, these observations indicate that transmembrane
TRP transport by the l-system may play a fundamental role in
regulating T cell responses in low TRP environments.
Transcellular transport systems of TRP and its metabolites may
thus offer an additional, yet underrecognized potential to influence
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the consequences of immunosuppressive TRP metabolism at the
T cell level to revert cancer-associated immune suppression.
SUMMARY
Recent advances in understanding the regulation as well as the cel-
lular and molecular targets of TRP metabolism have expanded the
opportunity to interfere with this pathway well beyond inhibiting
IDO. TDO is actively pursued as a target and multiple approved
drugs have been shown to interfere with IDO expression in cancer.
With our increased knowledge, future therapeutic strategies will
have to take downstream targets such as the AHR but also TRP
transport mechanisms into consideration, particularly as these
may be more easily and specifically targeted. At the same time,
preclinical studies have made clear that such pathway inhibitors
may not be active enough as a stand-alone therapeutic approach.
Thus, the rational combination with already available and/or yet
to be identified immunomodulatory strategies such as cancer vac-
cines or checkpoint inhibitors based on thorough basic research is
warranted. Continuing basic research on this highly conserved and
versatile pathway will expand not only our view on its pathophysi-
ological relevance but will also open novel therapeutic avenues for
defining novel therapeutic targets for diseases associated with an
aberrant immune tolerance, such as cancer, autoimmunity, allergy,
transplantation rejection, and infection.
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